Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey

Neukio Sees NK Promise

Executive Summary

After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.

You may also be interested in...



Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi

Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.

Oncology, Cell Therapy Developers Bag $175m In China

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'

The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel